A Phase 4 interventional study of Eptinezumab and Placebo in Migraine and Medication Overuse Headache, sponsored by H. Lundbeck A/S. Completed at 76 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 6th largest by enrollment, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 16th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 608 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 7th largest by enrollment, is one of 3 that started in 2022, is one of 3 in phase 4, and was the 19th registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications.
Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with headache, and acute medication use in adults who have migraine and MOH.
The total study duration from screening visit to safety follow-up visit is approximately 36 weeks and includes a screening period (4 weeks), a placebo-controlled period (12 weeks), an open-label period (12 weeks), and a safety follow-up period (8 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an intravenous (IV) infusion of eptinezumab at Week 0 and Week 12.
Drug: Eptinezumab
Participants will receive a single IV infusion of matching placebo to eptinezumab at Week 0. Then, all participants will receive a single IV infusion of eptinezumab at Week 12.
Drug: Eptinezumab · Drug: Placebo
Solution for infusion
Solution for infusion
Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
Time frame: Baseline, Weeks 1 - 4
Placebo-controlled Period: Change From Baseline in MMDs at Weeks 1 to 12
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
Time frame: Baseline, Weeks 1 - 12
Placebo-controlled Period: Change From Baseline in the Number of Monthly Headache Days (MHDs) at Weeks 1 to 4 and Weeks 1 to 12
A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).
Time frame: Baseline, Weeks 1 - 4 and Weeks 1 - 12
Placebo-controlled Period: Percentage of Participants Not Fulfilling the International Classification of Headache Disorders, 3rd Edition (ICHD-3) Diagnostic Criteria for Chronic Migraine (CM) Nor Medication Overuse Headache (MOH)
CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis. MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.
Time frame: Weeks 1 - 4 and Weeks 1 - 12
Placebo-controlled Period: Change From Baseline in Average Daily Pain Assessment Score at Weeks 1 to 2
Daily Pain assessment data were collected in the headache electronic diary (eDiary) via the question "What was the worst pain intensity of this headache today?". The pain intensity assessment was collected on a 3-point scale: Mild (score = 1), Moderate (score = 2), and Severe (score = 3). For each day, the Daily Pain assessment score was derived by averaging the worst pain intensity over all headaches of that day. For days on which no headaches took place during the relevant period, the Daily Pain score was given as a score of 0. The average Daily Pain score was calculated using the Daily Pain assessments collected during Weeks 1-2.
Time frame: Baseline, Weeks 1 - 2
Placebo-controlled Period: Change From Baseline in Monthly Days With Acute Migraine Medication Use at Weeks 1 to 4 and Weeks 1 to 12
Acute migraine medication included those medications classified as opioid, barbiturates, ergotamine, triptan, non-opioid analgesic, and combination of analgesic ingredients.
Time frame: Baseline, Weeks 1 - 4 and Weeks 1 - 12
Open-label Period: Change From Baseline in MMDs at Weeks 13-16, 17-20, and 21-24
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
Time frame: Baseline, Weeks 13-16, 17-20, and 21-24
Open-label Period: Change From Baseline in the Number of MHDs at Weeks 13-16, 17-20, and 21-24
A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).
Time frame: Baseline, at Weeks 13-16, 17-20, and 21-24
Open-label Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for CM Nor MOH at Weeks 13 to 24
CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis. MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.
Time frame: Weeks 13 - 24
Open-label Period: Change From Baseline in Average Daily Pain Assessment Score at Weeks 13-16, 17-20, and 21-24
Daily Pain assessment data were collected in the headache eDiary via the question "What was the worst pain intensity of this headache today?". The pain intensity assessment was collected on a 3-point scale: Mild (score = 1), Moderate (score = 2), and Severe (score = 3). For each day, the Daily Pain assessment score was derived by averaging the worst pain intensity over all headaches of that day. For days on which no headaches took place during the relevant period, the Daily Pain score was given as a score of 0. The average Daily Pain score was calculated using the Daily Pain assessments collected during Weeks 13-16, 17-20, and 21-24.
Time frame: Baseline, Weeks 13-16, 17-20, and 21-24
Open-label Period: Change From Baseline in Monthly Days With Acute Migraine Medication Use at Weeks 13-16, 17-20, and 21-24
Acute migraine medication included paracetamol, triptans, ergotamine, combination of non-opioid analgesics, individual non-opioid analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs). Barbiturates and/or opioid analgesics were allowed when considered medically indicated providing its use does not exceed 4 days per month.
Time frame: Baseline, Weeks 13-16, 17-20, and 21-24
Placebo-controlled Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for CM at Weeks 1 to 4 and Weeks 1 to 12
CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis.
Time frame: Weeks 1 - 4 and Weeks 1 - 12
Placebo-controlled Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for MOH at Weeks 1 to 4 and Weeks 1 to 12
MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.
Time frame: Weeks 1 - 4 and Weeks 1 - 12
Placebo-controlled Period: Change From Baseline in MMDs With Use of Acute Headache Medication at Weeks 1 to 12
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
Time frame: Baseline, Weeks 1 - 12
Placebo-controlled Period: Change From Baseline in Monthly Days With Triptan or Ergotamine Medication Use at Weeks 1 to 12
Time frame: Baseline, Weeks 1 - 12
Open-label Period: Change From Baseline in Monthly Days With Triptan or Ergotamine Medication Use at Weeks 13-16, 17-20, and 21-24
Time frame: Baseline, Weeks 13-16, 17-20, and 21-24
Placebo-controlled Period: Change From Baseline in Monthly Days With Individual Non-opioid Analgesics or Non-steroidal Anti-inflammatory Drug (NSAID) Medication Use at Weeks 1 to 12
Time frame: Baseline, Weeks 1 - 12
Open-label Period: Change From Baseline in Monthly Days With Individual Non-opioid Analgesics or NSAID Medication Use at Weeks 13-16, 17-20, and 21-24
Time frame: Baseline, Weeks 13-16, 17-20, and 21-24
Placebo-controlled Period: Change From Baseline in Monthly Days With Combination Non-opioid Analgesics Medication Use at Weeks 1 to 12
Time frame: Baseline, Weeks 1 - 12
Placebo-controlled Period: Number of Participants With Migraine on the Day After Dosing
Time frame: Day 1
Placebo-controlled Period: Percentage of Participants With ≥50% Reduction From Baseline in MMDs at Weeks 1 to 4 and Weeks 1 to 12
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
Time frame: Baseline to Weeks 1 - 4 and 1 - 12
Placebo-controlled Period: Percentage of Participants With ≥75% Reduction From Baseline in MMDs at Weeks 1 to 4 and Weeks 1 to 12
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
Time frame: Baseline to Weeks 1 - 4 and 1 - 12
Placebo-controlled Period: Percentage of Participants With ≥50% Reduction From Baseline in MHDs at Weeks 1 to 4 and Weeks 1 to 12
A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).
Time frame: Baseline to Weeks 1 - 4 and 1 - 12
Placebo-controlled Period: Percentage of Participants With ≥75% Reduction From Baseline in MHDs at Weeks 1 to 4 and Weeks 1 to 12
A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).
Time frame: Baseline to Weeks 1 - 4 and 1 - 12
Placebo-controlled Period: Change From Baseline in Percentage of Migraine Attacks With Severe Pain Intensity at Weeks 1 to 4 and Weeks 1 to 12
A migraine that fulfilled the criteria for a migraine, was referred to as a migraine attack.
Time frame: Baseline to Weeks 1 - 4 and 1 - 12
Placebo-controlled Period: Change From Baseline in Percentages of Headache Episodes With Severe Pain Intensity at Weeks 1 to 4 and Weeks 1 to 12
A non-migraine headache that lasted ≥30 minutes or a migraine headache, was referred to as a headache episode.
Time frame: Baseline to Weeks 1 - 4 and 1 - 12
Placebo-controlled Period: Patient Global Impression of Change (PGIC) Score at Weeks 4 and 12
The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.
Time frame: Weeks 4 and 12
Open-label Period: PGIC Score at Week 24
The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.
Time frame: Week 24
Placebo-controlled Period: Most Bothersome Symptom (MBS) Score at Week 12
Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.
Time frame: Week 12
Open-label Period: MBS Score at Week 24
Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.
Time frame: Week 24
Placebo-controlled Period: Change From Baseline in Headache Impact Test (HIT-6) Total Score at Weeks 4 and 12
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
Time frame: Baseline, Weeks 4 and 12
Open-label Period: Change From Baseline in HIT-6 Total Score at Week 24
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
Time frame: Week 24
Placebo-controlled Period: Change From Baseline in Modified Migraine Disability Assessment (mMIDAS) Total Score at Weeks 4 and 12
The mMIDAS is a self-administered questionnaire that contains 7 questions about the headache a participant had in the previous month. The first 5 questions assess the impact of migraine on 3 domains of daily activity: 2 questions for paid work or schoolwork, 2 questions for household work, and 1 question for family, social and leisure activities. The 2 questions for each of the first two groups assess, respectively, the number of days off due to headache, and the number of days in which the productivity was reduced by half or more. mMIDAS total score was derived from the sum of the answers on the first 5 questions. Total score ranged from 0 (little/no disability) to 20 (severe disability) with higher scores indicating more severe disability.
Time frame: Baseline, Weeks 4 and 12
Open-label Period: Change From Baseline in mMIDAS Total Score at Week 24
The mMIDAS is a self-administered questionnaire that contains 7 questions about the headache a participant had in the previous month. The first 5 questions assess the impact of migraine on 3 domains of daily activity: 2 questions for paid work or schoolwork, 2 questions for household work, and 1 question for family, social and leisure activities. The 2 questions for each of the first two groups assess, respectively, the number of days off due to headache, and the number of days in which the productivity was reduced by half or more. mMIDAS total score was derived from the sum of the answers on the first 5 questions. Total score ranged from 0 (little/no disability) to 20 (severe disability) with higher scores indicating more severe disability.
Time frame: Baseline, Week 24
Placebo-controlled Period: Change From Baseline in Migraine-Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Weeks 4 and 12
The MSQ v2.1 is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0-to-100-point scale. Higher scores indicated better quality of life.
Time frame: Baseline, Weeks 4 and 12
Open-label Period: Change From Baseline in MSQ v2.1 Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 24
The MSQ v2.1 is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0-to-100-point scale. Higher scores indicated better quality of life.
Time frame: Baseline, Weeks 24
Placebo-controlled Period: Change From Baseline in Euroqol 5 Dimension - 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Weeks 4 and 12
The EQ-5D-5L VAS measures participant's self-rated health-related quality of life on a VAS. The VAS score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline, Weeks 4 and 12
Open-label Period: Change From Baseline in EQ-5D-5L VAS Score at Week 24
The EQ-5D-5L VAS measures participant's self-rated health-related quality of life on a VAS. The VAS score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Week 24
Placebo-controlled Period: Change From Baseline in Work Productivity and Activity Impairment: Migraine (WPAI:M) Sub-scores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 12
The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
Time frame: Baseline, Week 12
Open-label Period: Change From Baseline in WPAI:M Sub-scores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 24
The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
Time frame: Baseline, Week 24
Placebo-controlled Period: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Subscale (Depression and Anxiety) Scores at Weeks 4 and 12
The HADS is a participant-rated scale designed to assess psychological distress in non-psychiatric participants. The HADS consists of 2 sub-scales: depression and anxiety. Each sub-scale contains 7 items, and each item was rated from 0 (absent) to 3 (maximum severity). The total score of each sub-scale ranged from 0 (absent) to 21 (maximum severity). Higher scores indicated higher severity.
Time frame: Baseline, Weeks 4 and 12
Open-label Period: Change From Baseline in HADS Subscale (Depression and Anxiety) Scores at Week 24
The HADS is a participant-rated scale designed to assess psychological distress in non-psychiatric participants. The HADS consists of 2 sub-scales: depression and anxiety. Each sub-scale contains 7 items, and each item was rated from 0 (absent) to 3 (maximum severity). The total score of each sub-scale ranged from 0 (absent) to 21 (maximum severity). Higher scores indicated higher severity.
Time frame: Baseline, Week 24
Placebo-controlled Period: Treatment Satisfaction Questionnaire for Medicine - 9 Items (TSQM-9) Score at Weeks 4 and 12
TSQM is a 14-item instrument consisting of four scales: effectiveness scale (questions 1 to 3), side effects scale (questions 4 to 8), convenience scale (questions 9 to 11) and global satisfaction scale (questions 12 to 14). In TSQM-9, the five items related to side effects of medication were not included. The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.
Time frame: Weeks 4 and 12
Open-label Period: TSQM-9 Score at Week 24
TSQM is a 14-item instrument consisting of four scales: effectiveness scale (questions 1 to 3), side effects scale (questions 4 to 8), convenience scale (questions 9 to 11) and global satisfaction scale (questions 12 to 14). In TSQM-9, the five items related to side effects of medication were not included. The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.
Time frame: Baseline, Week 24
Placebo-controlled Period: Migraine Specific Health Care Resource Utilization (HCRU) - Visits to a Family Doctor/General Practitioner at Baseline and Week 12
Number of participants who visited to a family doctor/general practitioner during the past 4 weeks has been reported at Baseline and Week 12.
Time frame: Baseline and Week 12
Placebo-controlled Period: Migraine Specific HCRU - Visits to a Specialist at Baseline and Week 12
Number of participants who visited a specialist during the past 4 weeks has been reported at Baseline and Week 12.
Time frame: Baseline and Week 12
Placebo-controlled Period: Migraine Specific HCRU - Number of Emergency Department Visits Due to Migraine at Baseline and Week 12
Number of participants who visited to the emergency department due to migraine during the past 4 weeks has been reported at Baseline and Week 12.
Time frame: Baseline and Week 12
Placebo-controlled Period: Migraine Specific HCRU - Number of Hospital Admissions Migraine at Baseline and Week 12
Number of participants who were admitted to the hospital during the past 4 weeks due to migraine has been reported at Baseline and Week 12.
Time frame: Baseline and Week 12
Placebo-controlled Period: Migraine Specific HCRU - Total Number of Participants With Overnight Hospital Stays Due to Migraine at Baseline and Week 12
Number of participants who had overnight hospital stays during the past 4 weeks due to migraine has been reported at Baseline and Week 12.
Time frame: Baseline and Week 12
Open-label Period: Migraine Specific HCRU - Visits to a Family Doctor/General Practitioner at Week 24
Number of participants who visited a family doctor/general practitioner has been reported.
Time frame: Week 24
Open-label Period: Migraine Specific HCRU - Visits to a Specialist at Week 24
Number of participants who visited a specialist has been reported.
Time frame: Week 24
Open-label Period: Migraine Specific HCRU - Number of Participants With Emergency Department Visits Due to Migraine at Week 24
Number of participants who visited the emergency department due to migraine has been reported.
Time frame: Week 24
Open-label Period: Migraine Specific HCRU - Number of Participants With Hospital Admissions Due to Migraine at Week 24
Number of participants who admitted in the hospital due to migraine has been reported.
Time frame: Week 24
Open-label Period: Migraine Specific HCRU - Number of Participants With Overnight Hospital Stays Due to Migraine at Week 24
Number of participants with overnight hospital stays due to migraine has been reported.
Time frame: Week 24
| Milestone | Eptinezumab | Placebo |
|---|---|---|
| Started | 305 | 303 |
| Received at least 1 dose of study drug | 303 | 301 |
| Full analysis set (fas) | 302 | 300 |
| Completed | 301 | 295 |
| Not completed | 4 | 8 |
| Withdrew: Withdrawal by subject | 0 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Failure to comply with trial procedures | 0 | 1 |
| Withdrew: Randomized but not treated | 2 | 2 |
| Withdrew: Other than specified | 1 | 1 |
| Milestone | Eptinezumab | Placebo |
|---|---|---|
| Started | 300 | 293 |
| Received at least 1 dose of study drug | 300 | 293 |
| Completed | 294 | 290 |
| Not completed | 6 | 3 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Other than specified | 1 | 2 |
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
| days/month | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4 | -6.85 ± 0.518 | -3.66 ± 0.519 |
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
| days/month | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Placebo-controlled Period: Change From Baseline in MMDs at Weeks 1 to 12 | -7.44 ± 0.508 | -4.50 ± 0.508 |
A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).
| days/month | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Change at Weeks 1-4 | -6.54 ± 0.502 | -3.40 ± 0.502 |
| Change at Weeks 1-12 | -7.38 ± 0.497 | -4.45 ± 0.497 |
CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis. MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.
| percentage of participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Weeks 1-4 | 37.8 | 18.1 |
| Weeks 1-12 | 27.2 | 12.7 |
Daily Pain assessment data were collected in the headache electronic diary (eDiary) via the question "What was the worst pain intensity of this headache today?". The pain intensity assessment was collected on a 3-point scale: Mild (score = 1), Moderate (score = 2), and Severe (score = 3). For each day, the Daily Pain assessment score was derived by averaging the worst pain intensity over all headaches of that day. For days on which no headaches took place during the relevant period, the Daily Pain score was given as a score of 0. The average Daily Pain score was calculated using the Daily Pain assessments collected during Weeks 1-2.
| units on a scale | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Placebo-controlled Period: Change From Baseline in Average Daily Pain Assessment Score at Weeks 1 to 2 | -0.58 ± 0.048 | -0.27 ± 0.048 |
Acute migraine medication included those medications classified as opioid, barbiturates, ergotamine, triptan, non-opioid analgesic, and combination of analgesic ingredients.
| days/month | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Change at Weeks 1-4 | -11.32 ± 0.508 | -7.69 ± 0.509 |
| Change at Weeks 1-12 | -11.18 ± 0.490 | -7.83 ± 0.490 |
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
| days/month | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Change at Weeks 13-16 | -10.23 ± 7.167 | -10.08 ± 7.136 |
| Change at Weeks 17-20 | -10.29 ± 7.093 | -10.29 ± 7.301 |
| Change at Weeks 21-24 | -9.24 ± 7.220 | -9.30 ± 7.602 |
A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).
| days/month | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Change at Weeks 13-16 | -10.31 ± 7.113 | -9.99 ± 7.082 |
| Change at Weeks 17-20 | -10.46 ± 6.941 | -10.34 ± 7.253 |
| Change at Weeks 21-24 | -9.46 ± 7.206 | -9.47 ± 7.382 |
CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis. MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.
| percentage of participants | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Open-label Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for CM Nor MOH at Weeks 13 to 24 | 38.9 | 40.2 |
Daily Pain assessment data were collected in the headache eDiary via the question "What was the worst pain intensity of this headache today?". The pain intensity assessment was collected on a 3-point scale: Mild (score = 1), Moderate (score = 2), and Severe (score = 3). For each day, the Daily Pain assessment score was derived by averaging the worst pain intensity over all headaches of that day. For days on which no headaches took place during the relevant period, the Daily Pain score was given as a score of 0. The average Daily Pain score was calculated using the Daily Pain assessments collected during Weeks 13-16, 17-20, and 21-24.
| units on a scale | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Change at Weeks 13-16 | -0.90 ± 0.628 | -0.90 ± 0.602 |
| Change at Weeks 17-20 | -0.88 ± 0.641 | -0.89 ± 0.630 |
| Change at Weeks 21-24 | -0.84 ± 0.638 | -0.81 ± 0.667 |
Acute migraine medication included paracetamol, triptans, ergotamine, combination of non-opioid analgesics, individual non-opioid analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs). Barbiturates and/or opioid analgesics were allowed when considered medically indicated providing its use does not exceed 4 days per month.
| days/month | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Change at Weeks 13-16 | -12.08 ± 6.738 | -11.67 ± 6.470 |
| Change at Weeks 17-20 | -11.82 ± 6.690 | -11.39 ± 7.080 |
| Change at Weeks 21-24 | -10.96 ± 6.693 | -10.44 ± 7.338 |
CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis.
| percentage of participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Weeks 1-4 | 55.0 | 32.4 |
| Weeks 1-12 | 44.4 | 23.0 |
MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.
| percentage of participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Weeks 1-4 | 52.2 | 31.9 |
| Weeks 1-12 | 40.1 | 24.0 |
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
| days/month | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Placebo-controlled Period: Change From Baseline in MMDs With Use of Acute Headache Medication at Weeks 1 to 12 | -10.32 ± 0.481 | -7.16 ± 0.481 |
| days/month | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Placebo-controlled Period: Change From Baseline in Monthly Days With Triptan or Ergotamine Medication Use at Weeks 1 to 12 | -8.35 ± 0.411 | -5.49 ± 0.409 |
| days/month | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Change at Weeks 13-16 | -8.70 ± 6.736 | -8.79 ± 6.781 |
| Change at Weeks 17-20 | -8.24 ± 6.540 | -8.31 ± 6.982 |
| Change at Weeks 21-24 | -7.43 ± 6.505 | -7.56 ± 6.700 |
| days/month | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Placebo-controlled Period: Change From Baseline in Monthly Days With Individual Non-opioid Analgesics or Non-steroidal Anti-inflammatory Drug (NSAID) Medication Use at Weeks 1 to 12 | -5.94 ± 0.402 | -4.80 ± 0.402 |
| days/month | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Change at Weeks 13-16 | -6.55 ± 7.205 | -6.66 ± 7.108 |
| Change at Weeks 17-20 | -6.65 ± 7.193 | -6.62 ± 7.316 |
| Change at Weeks 21-24 | -6.18 ± 7.018 | -6.44 ± 7.468 |
| days/month | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Placebo-controlled Period: Change From Baseline in Monthly Days With Combination Non-opioid Analgesics Medication Use at Weeks 1 to 12 | -1.24 ± 0.202 | -1.12 ± 0.201 |
| Participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Placebo-controlled Period: Number of Participants With Migraine on the Day After Dosing | 162 | 203 |
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
| percentage of participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Weeks 1-4 | 36.7 | 13.7 |
| Weeks 1-12 | 40.4 | 18.0 |
A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.
| percentage of participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Weeks 1-4 | 13.0 | 4.3 |
| Weeks 1-12 | 12.9 | 5.3 |
A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).
| percentage of participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Weeks 1-4 | 33.0 | 11.0 |
| Weeks 1-12 | 35.8 | 15.3 |
A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).
| percentage of participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Weeks 1-4 | 9.3 | 3.3 |
| Weeks 1-12 | 10.9 | 5.3 |
A migraine that fulfilled the criteria for a migraine, was referred to as a migraine attack.
| percentage of migraine attacks | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Change at Weeks 1-4 | -10.30 ± 1.912 | -1.60 ± 1.916 |
| Change at Weeks 1-12 | -5.21 ± 1.859 | -1.60 ± 1.860 |
A non-migraine headache that lasted ≥30 minutes or a migraine headache, was referred to as a headache episode.
| percentage of headache episodes | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Change at Weeks 1-4 | -11.78 ± 1.867 | -3.36 ± 1.872 |
| Change at Weeks 1-12 | -6.99 ± 1.822 | -2.79 ± 1.825 |
The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.
| units on a scale | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Week 4 | 2.62 ± 0.100 | 3.63 ± 0.100 |
| Week 12 | 2.64 ± 0.101 | 3.54 ± 0.101 |
The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.
| units on a scale | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Open-label Period: PGIC Score at Week 24 | 2.3 ± 1.18 | 2.3 ± 1.20 |
Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.
| units on a scale | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Placebo-controlled Period: Most Bothersome Symptom (MBS) Score at Week 12 | 2.87 ± 0.106 | 3.59 ± 0.107 |
Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.
| units on a scale | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Open-label Period: MBS Score at Week 24 | 2.6 ± 1.22 | 2.6 ± 1.25 |
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
| units on a scale | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Change at Week 4 | -6.5 ± 7.25 | -2.6 ± 5.30 |
| Change at Week 12 | -7.4 ± 8.60 | -3.9 ± 6.42 |
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
| units on a scale | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Open-label Period: Change From Baseline in HIT-6 Total Score at Week 24 | -8.1 ± 8.21 | -7.6 ± 7.74 |
The mMIDAS is a self-administered questionnaire that contains 7 questions about the headache a participant had in the previous month. The first 5 questions assess the impact of migraine on 3 domains of daily activity: 2 questions for paid work or schoolwork, 2 questions for household work, and 1 question for family, social and leisure activities. The 2 questions for each of the first two groups assess, respectively, the number of days off due to headache, and the number of days in which the productivity was reduced by half or more. mMIDAS total score was derived from the sum of the answers on the first 5 questions. Total score ranged from 0 (little/no disability) to 20 (severe disability) with higher scores indicating more severe disability.
| units on a scale | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Change at Week 4 | -14.73 ± 1.475 | -6.62 ± 1.476 |
| Change at Week 12 | -13.83 ± 1.494 | -8.76 ± 1.496 |
The mMIDAS is a self-administered questionnaire that contains 7 questions about the headache a participant had in the previous month. The first 5 questions assess the impact of migraine on 3 domains of daily activity: 2 questions for paid work or schoolwork, 2 questions for household work, and 1 question for family, social and leisure activities. The 2 questions for each of the first two groups assess, respectively, the number of days off due to headache, and the number of days in which the productivity was reduced by half or more. mMIDAS total score was derived from the sum of the answers on the first 5 questions. Total score ranged from 0 (little/no disability) to 20 (severe disability) with higher scores indicating more severe disability.
| units on a scale | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Open-label Period: Change From Baseline in mMIDAS Total Score at Week 24 | -17.3 ± 20.71 | -15.2 ± 19.69 |
The MSQ v2.1 is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0-to-100-point scale. Higher scores indicated better quality of life.
| units on a scale | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Change at Week 4: Role function- restrictive | 24.04 ± 1.898 | 10.15 ± 1.902 |
| Change at Week 12: Role function- restrictive | 22.55 ± 1.873 | 11.79 ± 1.877 |
| Change at Week 4: Role function- preventive | 18.58 ± 1.862 | 7.88 ± 1.864 |
| Change at Week 12: Role function- preventive | 17.96 ± 1.834 | 10.16 ± 1.836 |
| Change at Week 4: Emotional function | 23.82 ± 2.143 | 10.11 ± 2.145 |
| Change at Week 12: Emotional function | 22.06 ± 2.188 | 11.67 ± 2.193 |
The MSQ v2.1 is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0-to-100-point scale. Higher scores indicated better quality of life.
| units on a scale | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Role function- restrictive | 26.38 ± 23.302 | 26.33 ± 24.159 |
| Role function- preventive | 20.6 ± 23.61 | 20.7 ± 22.85 |
| Emotional function | 26.86 ± 27.806 | 26.54 ± 28.385 |
The EQ-5D-5L VAS measures participant's self-rated health-related quality of life on a VAS. The VAS score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
| units on a scale | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Change at Week 4 | 5.09 ± 1.561 | 0.49 ± 1.574 |
| Change at Week 12 | 7.43 ± 1.526 | 2.23 ± 1.540 |
The EQ-5D-5L VAS measures participant's self-rated health-related quality of life on a VAS. The VAS score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
| units on a scale | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Open-label Period: Change From Baseline in EQ-5D-5L VAS Score at Week 24 | 5.9 ± 22.69 | 3.9 ± 22.10 |
The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
| units on a scale | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Absenteeism | -4.73 ± 2.342 | -1.18 ± 2.324 |
| Presenteeism | -19.10 ± 2.602 | -10.12 ± 2.544 |
| Work productivity loss | -19.88 ± 2.790 | -9.04 ± 2.727 |
| Activity impairment | -18.87 ± 2.065 | -10.42 ± 2.079 |
The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
| units on a scale | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Absenteeism | -9.22 ± 27.236 | -4.75 ± 25.007 |
| Presenteeism | -18.8 ± 28.41 | -22.7 ± 27.58 |
| Work productivity loss | -20.54 ± 29.162 | -24.18 ± 29.102 |
| Activity impairment | -19.6 ± 28.14 | -21.0 ± 28.73 |
The HADS is a participant-rated scale designed to assess psychological distress in non-psychiatric participants. The HADS consists of 2 sub-scales: depression and anxiety. Each sub-scale contains 7 items, and each item was rated from 0 (absent) to 3 (maximum severity). The total score of each sub-scale ranged from 0 (absent) to 21 (maximum severity). Higher scores indicated higher severity.
| units on a scale | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Change at Week 4: Total Depression Score | -1.59 ± 0.294 | -0.61 ± 0.296 |
| Change at Week 12: Total Depression Score | -1.82 ± 0.300 | -0.64 ± 0.302 |
| Change at Week 4: Total Anxiety Score | -1.32 ± 0.262 | -0.49 ± 0.263 |
| Change at Week 12: Total Anxiety Score | -1.37 ± 0.257 | -0.40 ± 0.257 |
The HADS is a participant-rated scale designed to assess psychological distress in non-psychiatric participants. The HADS consists of 2 sub-scales: depression and anxiety. Each sub-scale contains 7 items, and each item was rated from 0 (absent) to 3 (maximum severity). The total score of each sub-scale ranged from 0 (absent) to 21 (maximum severity). Higher scores indicated higher severity.
| units on a scale | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Total Depression Score | -2.1 ± 3.78 | -1.3 ± 3.88 |
| Total Anxiety Score | -2.0 ± 3.36 | -1.1 ± 3.54 |
TSQM is a 14-item instrument consisting of four scales: effectiveness scale (questions 1 to 3), side effects scale (questions 4 to 8), convenience scale (questions 9 to 11) and global satisfaction scale (questions 12 to 14). In TSQM-9, the five items related to side effects of medication were not included. The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.
| units on a scale | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Week 4: Effectiveness Score | 58.21 ± 2.228 | 39.01 ± 2.236 |
| Week 12: Effectiveness Score | 57.95 ± 2.264 | 40.89 ± 2.278 |
| Week 4: Convenience Score | 69.60 ± 1.736 | 63.62 ± 1.743 |
| Week 12: Convenience Score | 69.42 ± 1.786 | 63.12 ± 1.797 |
| Week 4: Overall Satisfaction Score | 59.56 ± 2.094 | 43.57 ± 2.099 |
| Week 12: Overall Satisfaction Score | 62.54 ± 2.136 | 46.98 ± 2.146 |
TSQM is a 14-item instrument consisting of four scales: effectiveness scale (questions 1 to 3), side effects scale (questions 4 to 8), convenience scale (questions 9 to 11) and global satisfaction scale (questions 12 to 14). In TSQM-9, the five items related to side effects of medication were not included. The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.
| units on a scale | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| Effectiveness Score | 63.23 ± 28.684 | 62.50 ± 27.896 |
| Convenience Score | 66.23 ± 21.451 | 66.02 ± 23.017 |
| Overall Satisfaction Score | 64.23 ± 29.401 | 63.51 ± 27.603 |
Number of participants who visited to a family doctor/general practitioner during the past 4 weeks has been reported at Baseline and Week 12.
| Participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Baseline — 0 Visit | 213 | 198 |
| Baseline — 1 Visit | 44 | 42 |
| Baseline — 2 Visits | 10 | 17 |
| Baseline — 3 Visits | 11 | 4 |
| Baseline — 4 Visits | 2 | 3 |
| Baseline — 5 Visits | 1 | 2 |
| Baseline — 6 Visits | 1 | 0 |
| Baseline — 10 Visits | 1 | 0 |
| Baseline — 15 Visits | 0 | 1 |
| Week 12 — 0 Visit | 242 | 217 |
| Week 12 — 1 Visit | 29 | 41 |
| Week 12 — 2 Visits | 7 | 15 |
| Week 12 — 3 Visits | 5 | 4 |
| Week 12 — 4 Visits | 4 | 2 |
| Week 12 — 5 Visits | 0 | 2 |
| Week 12 — 6 Visits | 1 | 0 |
| Week 12 — 10 Visits | 0 | 0 |
| Week 12 — 15 Visits | 0 | 0 |
Number of participants who visited a specialist during the past 4 weeks has been reported at Baseline and Week 12.
| Participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Baseline — 0 Visit | 180 | 156 |
| Baseline — 1 Visit | 71 | 83 |
| Baseline — 2 Visits | 21 | 18 |
| Baseline — 3 Visits | 6 | 5 |
| Baseline — 4 Visits | 3 | 2 |
| Baseline — 5 Visits | 1 | 2 |
| Baseline — 6 Visits | 1 | 0 |
| Baseline — 12 Visits | 0 | 1 |
| Week 12 — 0 Visit | 245 | 224 |
| Week 12 — 1 Visit | 30 | 43 |
| Week 12 — 2 Visits | 7 | 8 |
| Week 12 — 3 Visits | 1 | 5 |
| Week 12 — 4 Visits | 4 | 1 |
| Week 12 — 5 Visits | 1 | 0 |
| Week 12 — 6 Visits | 0 | 0 |
| Week 12 — 12 Visits | 0 | 0 |
Number of participants who visited to the emergency department due to migraine during the past 4 weeks has been reported at Baseline and Week 12.
| Participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Baseline — 0 Visit | 275 | 256 |
| Baseline — 1 Visit | 7 | 7 |
| Baseline — 2 Visits | 1 | 3 |
| Baseline — 9 Visits | 0 | 1 |
| Week 12 — 0 Visit | 281 | 268 |
| Week 12 — 1 Visit | 5 | 10 |
| Week 12 — 2 Visits | 2 | 3 |
| Week 12 — 9 Visits | 0 | 0 |
Number of participants who were admitted to the hospital during the past 4 weeks due to migraine has been reported at Baseline and Week 12.
| Participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Baseline — 0 Admission | 279 | 258 |
| Baseline — 1 Admission | 3 | 7 |
| Baseline — 2 Admissions | 1 | 1 |
| Baseline — 16 Admissions | 0 | 1 |
| Week 12 — 0 Admission | 286 | 277 |
| Week 12 — 1 Admission | 2 | 4 |
| Week 12 — 2 Admissions | 0 | 0 |
| Week 12 — 16 Admissions | 0 | 0 |
Number of participants who had overnight hospital stays during the past 4 weeks due to migraine has been reported at Baseline and Week 12.
| Participants | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo |
|---|---|---|
| Baseline — 0 Stay | 282 | 264 |
| Baseline — 1 Stay | 1 | 1 |
| Baseline — 2 Stays | 0 | 1 |
| Baseline — 7 Stays | 0 | 1 |
| Week 12 — 0 Stay | 287 | 278 |
| Week 12 — 1 Stay | 1 | 3 |
| Week 12 — 2 Stays | 0 | 0 |
| Week 12 — 7 Stays | 0 | 0 |
Number of participants who visited a family doctor/general practitioner has been reported.
| Participants | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| 0 Visit | 239 | 239 |
| 1 Visit | 26 | 20 |
| 2 Visits | 11 | 13 |
| 3 Visits | 3 | 1 |
| 4 Visits | 1 | 0 |
| 5 Visits | 0 | 1 |
| 7 Visits | 0 | 1 |
| 8 Visits | 0 | 0 |
| 13 Visits | 1 | 0 |
Number of participants who visited a specialist has been reported.
| Participants | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| 0 Visit | 239 | 240 |
| 1 Visit | 29 | 20 |
| 2 Visits | 7 | 8 |
| 3 Visits | 3 | 4 |
| 4 Visits | 1 | 2 |
| 5 Visits | 0 | 1 |
| 6 Visits | 1 | 0 |
| 7 Visits | 1 | 0 |
Number of participants who visited the emergency department due to migraine has been reported.
| Participants | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| 0 Visit | 277 | 265 |
| 1 Visit | 3 | 5 |
| 2 Visits | 0 | 3 |
| 3 Visits | 0 | 1 |
| 10 Visits | 0 | 1 |
| 18 Visits | 1 | 0 |
Number of participants who admitted in the hospital due to migraine has been reported.
| Participants | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| 0 Admission | 281 | 271 |
| 1 Admission | 0 | 2 |
| 2 Admissions | 0 | 2 |
Number of participants with overnight hospital stays due to migraine has been reported.
| Participants | Open-label Period: Eptinezumab - Eptinezumab | Open-label Period: Placebo - Eptinezumab |
|---|---|---|
| 0 Stay | 281 | 270 |
| 1 Stays | 0 | 3 |
| 2 Stays | 0 | 1 |
| 12 Stays | 0 | 1 |
Collected over Up to 32 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-controlled Period: Eptinezumab | 0/303 (0%) | 2/303 (0.7%) | 50/303 (16.5%) |
| Placebo-controlled Period: Placebo | 0/301 (0%) | 1/301 (0.3%) | 55/301 (18.3%) |
| Open-label Period: Eptinezumab to Eptinezumab | 0/300 (0%) | 2/300 (0.7%) | 30/300 (10%) |
| Open-label Period: Placebo to Eptinezumab | 0/293 (0%) | 5/293 (1.7%) | 42/293 (14.3%) |
| Event | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo | Open-label Period: Eptinezumab to Eptinezumab | Open-label Period: Placebo to Eptinezumab |
|---|---|---|---|---|
| HaemorrhoidsGastrointestinal disorders | 0/303 | 0/301 | 0/300 | 1/293 |
| Breast cancer stage IIINeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/303 | 0/301 | 0/300 | 1/293 |
| MigraineNervous system disorders | 0/303 | 0/301 | 0/300 | 1/293 |
| SyncopeNervous system disorders | 0/303 | 0/301 | 0/300 | 1/293 |
| Transient ischaemic attackNervous system disorders | 0/303 | 0/301 | 0/300 | 1/293 |
| Suicide attemptPsychiatric disorders | 0/303 | 0/301 | 0/300 | 1/293 |
| Chest painGeneral disorders | 0/303 | 0/301 | 1/300 | 0/293 |
| Ankle fractureInjury, poisoning and procedural complications | 0/303 | 0/301 | 1/300 | 0/293 |
| Drug abusePsychiatric disorders | 0/303 | 1/301 | 0/300 | 0/293 |
| AppendicitisInfections and infestations | 1/303 | 0/301 | 0/300 | 0/293 |
| Event | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo | Open-label Period: Eptinezumab to Eptinezumab | Open-label Period: Placebo to Eptinezumab |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 15/303 | 17/301 | 7/300 | 10/293 |
| FatigueGeneral disorders | 6/303 | 11/301 | 6/300 | 5/293 |
| InfluenzaInfections and infestations | 11/303 | 10/301 | 7/300 | 6/293 |
| DizzinessNervous system disorders | 8/303 | 9/301 | 1/300 | 8/293 |
| InsomniaPsychiatric disorders | 2/303 | 8/301 | 2/300 | 3/293 |
| Back painMusculoskeletal and connective tissue disorders | 5/303 | 7/301 | 3/300 | 4/293 |
| AstheniaGeneral disorders | 3/303 | 3/301 | 1/300 | 6/293 |
| COVID-19Infections and infestations | 6/303 | 4/301 | 5/300 | 6/293 |
All-Participants-Treated Set (APTS) included all randomized participants who received an infusion of the IMP in the Placebo-controlled Period.
| Age, Continuous(years) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Mean | 45.7 ± 11.95 | 45.2 ± 12.03 | 45.5 ± 11.98 |
| Sex: Female, Male(Participants) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Female | 264 | 253 | 517 |
| Male | 39 | 48 | 87 |
| Race/Ethnicity, Customized(Participants) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Race — White | 151 | 147 | 298 |
| Race — Black | 3 | 4 | 7 |
| Race — Asian | 1 | 1 | 2 |
| Race — Other | 2 | 4 | 6 |
| Race — Not Collected/Unknown | 146 | 145 | 291 |
| Monthly Migraine Days (MMDs)(days/month) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Mean | 21.0 ± 4.26 | 20.9 ± 4.28 | 20.9 ± 4.27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2022 to primary completion in Oct 2024, 27 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 27 months is close to that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab